Cargando…

Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer

Small cell lung cancer (SCLC) has a poor prognosis and is found disseminated at first presentation in the majority of cases. The cell biological mechanisms underlying metastasis and drug resistance are not clear. SCLC is characterized by high numbers of circulating tumor cells (CTCs) and we were abl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamilton, Gerhard, Rath, Barbara, Klameth, Lukas, Hochmair, Maximilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549360/ https://www.ncbi.nlm.nih.gov/pubmed/26328272

Ejemplares similares

Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2019)

Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
por: Rath, Barbara, et al.
Publicado: (2023)

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
por: Hochmair, Maximilian, et al.
Publicado: (2019)

Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells
por: STICKLER, SANDRA, et al.
Publicado: (2023)

Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines
por: Rath, Barbara, et al.
Publicado: (2018)

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines
por: Hamilton, Gerhard, et al.
Publicado: (2014)

Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance
por: Klameth, Lukas, et al.
Publicado: (2017)

Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
por: Rath, Barbara, et al.
Publicado: (2020)

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
por: Plangger, Adelina, et al.
Publicado: (2021)

In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
por: Klameth, Lukas, et al.
Publicado: (2017)

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2019)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Significance of circulating tumor cells in lung cancer: a narrative review
por: Hamilton, Gerhard, et al.
Publicado: (2023)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2021)

Role of circulating tumor cell spheroids in drug resistance
por: Hamilton, Gerhard, et al.
Publicado: (2019)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
por: Plangger, Adelina, et al.
Publicado: (2022)

How to target small cell lung cancer
por: Hamilton, Gerhard, et al.
Publicado: (2015)

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
por: Hochmair, Maximilian
Publicado: (2018)

Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer
por: He, Wenjie, et al.
Publicado: (2016)

Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients
por: Yang, Baohong, et al.
Publicado: (2017)

Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
por: Wei, Zhangjing, et al.
Publicado: (2017)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase
por: Mattila, Elina, et al.
Publicado: (2010)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer
por: Jiang, Li, et al.
Publicado: (2022)

Cell-free expression of functional receptor tyrosine kinases
por: He, Wei, et al.
Publicado: (2015)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
por: Li, Yan, et al.
Publicado: (2022)

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014)

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors
por: Secky, Lena, et al.
Publicado: (2013)

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r34vcu1ljpil2jiq4568rbp1c0